Targeted therapy monitoring of BRAF-V600-mutant Erdheim-Chester disease by fast quantitative whole-body bone CZT-tomoscintigraphies.
Fiche publication
Date publication
janvier 2023
Journal
European journal of hybrid imaging
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MARIE Pierre-Yves, Pr VERGER Antoine
Tous les auteurs :
Melki S, Moulinet T, Verger A, Marie PY, Imbert L, Bahloul A
Lien Pubmed
Résumé
Erdheim-Chester disease (ECD) is a rare histiocytosis due to proto-oncogene mutations, primarily affecting the long bones and possibly being treated by novel targeted therapies. F-FDG PET is a reference technique for ECD assessment. However, we present a case where easier and more objective monitoring of the ECD-related bone metabolism abnormalities under treatment was obtained with the standardized uptake value-based information provided by fast whole-body [Tc-99 m]-HDP bone tomoscintigraphies (QWBT) recorded with a high-sensitivity CZT-camera/computed tomography (CT) hybrid system.
Mots clés
CZT-camera, Erdheim-Chester disease, Targeted therapy, Whole-body bone tomoscintigraphy, [F-18]-FDG PET
Référence
Eur J Hybrid Imaging. 2023 01 13;7(1):1